George Eric  Davis net worth and biography

George Davis Biography and Net Worth

Mr. George Eric Davis has been an Executive Vice President at BioMarin Pharmaceutical Inc. since December 30, 2015 and has been its General Counsel and Secretary since 2004. Mr. Davis served as Senior Vice President at BioMarin Pharmaceutical Inc. from December 2005 to March 2016. Mr. Davis served as an Assistant Secretary of BioMarin Pharmaceutical Inc. and served as its Vice President from 2004 to December 2005. He joined Biomarin Pharmaceutical Inc. in March 2004. From 2000 to 2004, he worked in the San Francisco office of Paul Hastings, Janofsky & Walker LLP, where he was an associate in the Corporate Department and served on its national securities practice committee. He serves as a Member of Supervisory Board at Prosensa Holding N.V. Mr. Davis received a B.A from the University of California, Berkeley and a J.D. from the University of San Francisco.

What is George Eric Davis' net worth?

The estimated net worth of George Eric Davis is at least $4.95 million as of March 28th, 2024. Mr. Davis owns 55,856 shares of BioMarin Pharmaceutical stock worth more than $4,950,517 as of April 21st. This net worth estimate does not reflect any other investments that Mr. Davis may own. Additionally, Mr. Davis receives an annual salary of $1,230,000.00 as EVP at BioMarin Pharmaceutical. Learn More about George Eric Davis' net worth.

How old is George Eric Davis?

Mr. Davis is currently 53 years old. There are 4 older executives and no younger executives at BioMarin Pharmaceutical. The oldest executive at BioMarin Pharmaceutical is Dr. Henry J. Fuchs M.D., Ph.D., President of Worldwide Research & Development, who is 66 years old. Learn More on George Eric Davis' age.

What is George Eric Davis' salary?

As the EVP of BioMarin Pharmaceutical Inc., Mr. Davis earns $1,230,000.00 per year. The highest earning executive at BioMarin Pharmaceutical is Dr. Henry J. Fuchs M.D., Ph.D., President of Worldwide Research & Development, who commands a salary of $1,490,000.00 per year. Learn More on George Eric Davis' salary.

How do I contact George Eric Davis?

The corporate mailing address for Mr. Davis and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected]. Learn More on George Eric Davis' contact information.

Has George Eric Davis been buying or selling shares of BioMarin Pharmaceutical?

George Eric Davis has not been actively trading shares of BioMarin Pharmaceutical during the past quarter. Most recently, George Eric Davis sold 24,602 shares of the business's stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $88.34, for a transaction totalling $2,173,340.68. Following the completion of the sale, the executive vice president now directly owns 55,856 shares of the company's stock, valued at $4,934,319.04. Learn More on George Eric Davis' trading history.

Who are BioMarin Pharmaceutical's active insiders?

BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Mark Alles (Director), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), Charles Guyer (EVP), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.

Are insiders buying or selling shares of BioMarin Pharmaceutical?

In the last twelve months, insiders at the biotechnology company sold shares 16 times. They sold a total of 198,993 shares worth more than $18,013,156.26. The most recent insider tranaction occured on April, 12th when Director Jean Jacques Bienaime sold 20,000 shares worth more than $1,825,200.00. Insiders at BioMarin Pharmaceutical own 1.8% of the company. Learn More about insider trades at BioMarin Pharmaceutical.

Information on this page was last updated on 4/12/2024.

George Eric Davis Insider Trading History at BioMarin Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/28/2024Sell24,602$88.34$2,173,340.6855,856View SEC Filing Icon  
12/13/2023Sell13,764$95.30$1,311,709.2055,710View SEC Filing Icon  
8/8/2023Sell11,000$89.42$983,620.0069,474View SEC Filing Icon  
7/8/2022Sell7,398$90.00$665,820.0058,941View SEC Filing Icon  
5/2/2022Sell15,347$80.38$1,233,591.8666,339View SEC Filing Icon  
3/21/2022Sell6,129$81.29$498,226.41View SEC Filing Icon  
5/3/2021Sell4,673$78.30$365,895.9068,781View SEC Filing Icon  
4/19/2021Sell2,709$79.58$215,582.2271,149View SEC Filing Icon  
5/1/2020Sell12,504$89.38$1,117,607.5278,181View SEC Filing Icon  
11/26/2019Sell3,190$79.66$254,115.4068,709View SEC Filing Icon  
3/25/2019Sell3,363$87.86$295,473.1875,253View SEC Filing Icon  
9/13/2018Sell12,000$99.57$1,194,840.0074,950View SEC Filing Icon  
3/23/2018Sell3,350$81.35$272,522.5087,989View SEC Filing Icon  
3/16/2018Sell3,818$83.88$320,253.8494,634View SEC Filing Icon  
3/5/2018Sell2,105$79.04$166,379.2090,089View SEC Filing Icon  
2/1/2018Sell30,000$90.66$2,719,800.00112,942View SEC Filing Icon  
11/30/2017Sell1,200$85.64$102,768.00View SEC Filing Icon  
6/23/2017Sell9,844$96.60$950,930.4093,425View SEC Filing Icon  
6/5/2017Sell9,471$91.04$862,239.8474,342View SEC Filing Icon  
5/5/2017Sell2,500$100.34$250,850.0085,251View SEC Filing Icon  
3/16/2017Sell2,238$91.96$205,806.4875,967View SEC Filing Icon  
3/6/2017Sell1,498$93.32$139,793.3678,962View SEC Filing Icon  
8/1/2016Sell2,167$100.00$216,700.0071,158View SEC Filing Icon  
7/7/2016Sell2,167$90.00$195,030.0072,836View SEC Filing Icon  
5/10/2016Sell14,658$85.11$1,247,542.3891,894View SEC Filing Icon  
3/14/2016Sell1,996$86.21$172,075.1676,190View SEC Filing Icon  
12/16/2015Sell1,362$100.00$136,200.0066,156View SEC Filing Icon  
5/18/2015Sell2,558$125.26$320,415.08View SEC Filing Icon  
3/2/2015Sell23,000$108.31$2,491,130.00View SEC Filing Icon  
11/25/2014Sell20,000$89.75$1,795,000.00View SEC Filing Icon  
9/19/2014Sell17,536$69.75$1,223,136.00View SEC Filing Icon  
5/14/2013Sell20,000$70.34$1,406,800.00View SEC Filing Icon  
3/4/2013Sell4,000$60.18$240,720.00View SEC Filing Icon  
11/12/2012Sell99,075$48.45$4,800,183.75View SEC Filing Icon  
See Full Table

George Eric Davis Buying and Selling Activity at BioMarin Pharmaceutical

This chart shows George Eric Davis's buying and selling at BioMarin Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $88.63
Low: $88.29
High: $90.18

50 Day Range

MA: $87.61
Low: $83.81
High: $92.22

2 Week Range

Now: $88.63
Low: $76.02
High: $99.56


1,778,647 shs

Average Volume

1,290,770 shs

Market Capitalization

$16.73 billion

P/E Ratio


Dividend Yield